Pembrolizumab and diabetes: a case of diabetic ketoacidosis in a patient with metastatic melanoma

Mahoney K, Freeman G, McDermott D. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Thera 2015;37(4):764-82. https://doi.org/10.1016/j.clinthera.2015.02.018

Francisco L, Sage P, Sharpe A. The PD-1 pathway in tolerance and autoimmunity. Immunol Reviews 2010;236(1):219-42. https://doi.org/10.1111/j.1600-065X.2010.00923.x

Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One 2016;11(7):e0160221. https://doi.org/10.1371/journal.pone.0160221.

de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res 2019;51:145–56. https://doi.org/10.1055/a-0843-3366

Hughes J, Vudattu N, Sznol M, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 2015;38:e55-e57. https://doi.org/10.2337/dc14-2349

Okamoto M, Okamoto M, Gotoh K, et al. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy. J Diabetes Investig 2016; 7:915-18. https://doi.org/10.1111/jdi.12531

Fife B, Guleria I, Bupp M, et al. The programmed death-1 (PD-1) pathway regulates peripheral T cell tolerance during autoimmune diabetes in nonobese diabetic (NOD) mice. Clinical Immunology 2007;123:S27. https://doi.org/10.1016/j.clim.2007.03.248

Fujisawa R, Haseda F, Tsutsumi C, et al. Low programmed cell death-1 (PD- 1) expression in peripheral CD4+T cells in Japanese patients with autoimmune type 1 diabetes. Clinical Experimental Immunol 2015;180(3): 452–7. https://doi.org/10.1111/cei.12603

Hao J, Renno A, Imam S, Alfonso-Jaume M, Elnagar N, Jaume J. Development of type 1 diabetes after cancer immunotherapy. AACE Clinical Case Reports 2017;3(3):e242-e245. https://doi.org/10.4158/EP161410.CR

Quandt Z, Young A, Anderson M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin Exp Immunol 2020; 200:131–40. https://doi.org/10.1111/cei.13424

Kotwal A, Haddox C, Block M, Kudva YC. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care 2019;7:e000591. https://doi.org/10.1136/bmjdrc-2018-000591

Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral damage: insulin- dependent diabetes induced with checkpoint inhibitors. Diabetes 2018; 67:1471–80. https://doi.org/10.2337/dbi18-0002

Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Suppl 4):iv264–6. https://doi.org/10.1093/annonc/mdx225

Angelousi A, Chatzellis E, Kaltsas G. New Molecular, Biological, and Immunological Agents Inducing Hypophysitis. Neuroendocrinology 2017; 106(1):89-100